Dolutegravir Monotherapy as Treatment De-Escalation in HIV-Infected Adults with Virological Control: DoluMono Cohort Results
Antiviral Therapy2016Vol. 22(2), pp. 169–172
Citations Over TimeTop 10% of 2016 papers
Celia Oldenbuettel, Eva Wolf, Ayla Ritter, Sebastian Noé, Silke Heldwein, Rita Pascucci, Carmen Wiese, Ariane von Krosigk, Eva Jaegel-Guedes, Hans Jaeger, Annamaria Balogh, C Koegl, Christoph D. Spinner
Abstract
De-escalating to DTG monotherapy in selected patients might be a safe and feasible option. However, in one case evolution of INSTI resistance was observed. Further studies should assess particular risk factors for DTG monotherapy failure. In the meanwhile, caution is warranted.
Related Papers
- → Dolutegravir (S/GSK1349572) Exhibits Significantly Slower Dissociation than Raltegravir and Elvitegravir from Wild-Type and Integrase Inhibitor-Resistant HIV-1 Integrase-DNA Complexes(2011)221 cited
- → Mutations Located outside the Integrase Gene Can Confer Resistance to HIV-1 Integrase Strand Transfer Inhibitors(2017)93 cited
- → Prevalent Polymorphisms in Wild-Type HIV-1 Integrase Are Unlikely To Engender Drug Resistance to Dolutegravir (S/GSK1349572)(2013)19 cited
- → The dolutegravir R263K resistance mutation in HIV-1 integrase is incompatible with the emergence of resistance against raltegravir(2015)13 cited
- → The HIV-1 integrase E157Q polymorphism per se does not alter susceptibility to raltegravir and dolutegravir in vitro(2017)14 cited